Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Recent clinical trials revealed that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce cardiovascular events in type 2 diabetic patients, however, canagliflozin increased limb amputations, an effect not seen with other SGLT2 inhibitors. Since endothelial cell (EC) dysfunction p...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2019-04-01
|
| Serija: | Frontiers in Pharmacology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/article/10.3389/fphar.2019.00362/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|